About Sweta Vijayan
Sweta holds a degree in Economics. Her fundamental approach in analyzing different financial instruments helps investors identify untapped investment opportunities.
Recent Articles By Sweta Vijayan
Better Buy for 2022: IBM vs. Xerox
The growing demand for tech products and services and rising government and corporate investments should enable the technology industry to keep growing. As the looming interest rate hikes lead to market volatility, dividend-paying tech stocks International Business Machines (IBM) and Xerox Holdings (XRX) should attract investors’ attention. But which of these stocks is a better buy now? Read more to find out.
4 Auto Manufacturing Stocks With more Upside Than Ford Motor, According to Wall Street
Despite attracting much investor attention with the launch of new electric vehicles, Ford Motor (F) has been suffering due to a semiconductor chip shortage and high input costs. We think that in contrast, their strong financials and deliveries should help Daimler (DDAIF), General Motors (GM), Stellantis (STLA), and NIO (NIO) perform better than F in the coming months. Read on.
Better Buy for 2022: Caterpillar vs. Deere
The demand for heavy machinery and equipment in agriculture and construction activities has been driving growth. Therefore, both Caterpillar (CAT) and Deere (DE) should benefit. But which of these stocks is a better buy now? Read more to find out.
5 Semiconductor Stocks That Outperformed Bitcoin in 2021
Despite hitting record-highs in November, bitcoin lost ground at the year-end on several concerns. However, the prominent semiconductor industry benefited from the surging demand for chips and rising investments to ramp up production. As a result, notable semiconductor stocks NVIDIA (NVDA), Marvell (MRVL), ON Semiconductor (ON), Synaptics (SYNA), and Lattice Semiconductor (LSCC) outperformed Bitcoin in 2021.
Better Buy for 2022: Merck vs. AstraZeneca
Given rising investments and medical breakthroughs, the dire need for COVID-19 vaccines and pills, and the pressing need to treat several other diseases, the pharmaceutical industry should continue growing this year and beyond. We think prominent companies in this space, Merck & Co. (MRK) and AstraZeneca (AZN), are well-positioned to capitalize on the industry tailwinds. But which of these stocks is a better buy now? Read more to learn our view.
4 Top Health Insurance Stocks to Buy in January
Health insurers have been seeing mixed enrollment trends, and increasing competition and rising medical expenses remain concerns. However, the lesser impact of the COVID-19 omicron variant and subsidies in the individual market should drive the industry’s growth in the coming quarters. So, we think it could be wise to bet now on top health insurance stocks UnitedHealth (UNH), Anthem (ANTM), Cigna (CI), and Centene (CNC). Read on.
5 Software Stocks That Plunged More Than 20% Last Week
Investors recently began rotating out of expensive software stocks on the Fed’s signal of its more hawkish stance. Against this backdrop, software stocks Atlassian (TEAM), HubSpot (HUBS), HashiCorp (HCP), monday.com (MNDY), and Globant (GLOB) declined more than 20% in price last week. So, read on for a discussion of these companies’ fundamentals.
Fortinet vs. Qualys: Which Cybersecurity Stock is a Better Buy?
Over the last couple of years, the world has experienced an increase in cyberattacks and data breaches. This has been driving the demand for cybersecurity solutions. Since this industry is expected to continue gaining momentum this year, prominent cybersecurity players Fortinet (FTNT) and Qualys (QLYS) should benefit. But which of these stocks is a better buy now? Read more to find out.
Weibo vs. iQIYI: Which Chinese Internet Stock is a Better Buy?
Despite facing regulatory pressures internationally, the country’s self-reliance strategy and improved user experience should benefit Chinese companies in the long term. Prominent Chinese internet stocks Weibo Corporation (WB) and iQIYI (IQ) should benefit. But which of these stocks is a better buy now? Read more to find out.